US2018177781A1PendingUtilityA1

Novel crystalline forms

56
Assignee: VM THERAPEUTICS LLCPriority: Mar 15, 2013Filed: Aug 4, 2017Published: Jun 28, 2018
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Jay Jie-Qiang Wu
A61K 31/519C07D 471/04
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel crystalline polymorphic forms of 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. The present invention also includes the methods of making crystalline polymorphic forms thereof and the use thereof for preparing a pharmaceutical composition.

Claims

exact text as granted — not AI-modified
1 . A crystalline polymorph Form 2 of compound 10 
       
         
           
           
               
               
           
         
       
     
     
         2 .- 134 . (canceled)

Join the waitlist — get patent alerts

Track US2018177781A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.